Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology, Inc. filings document the regulatory record for a public biotechnology company developing engineered-cell medicines. Recent 8-K reports disclose operating results, corporate presentations, program updates for UP421, SC451, and SG293, at-the-market common stock sales arrangements, executive appointments, and board-class governance matters.
Proxy materials describe annual meeting voting items, director elections, board structure, executive compensation, and stockholder governance procedures. The company’s filings also capture material agreements, capital-structure disclosures, Regulation FD presentations, and other event reports tied to its cell-therapy pipeline and public-company obligations.
Sana Biotechnology, Inc. disclosed that Mary Agnes Wilderotter has decided to resign from its Board of Directors, effective August 29, 2025. She is also stepping down as Chairperson of the Nominating and Corporate Governance Committee and as a member of the Audit Committee.
The company states that Ms. Wilderotter’s resignation is not due to any disagreement with Sana on matters related to its operations, policies, or practices. This indicates a governance change but not one tied to a reported dispute over the company’s direction or management.
Sana Biotechnology reported continued development-stage losses and significant balance sheet changes through June 30, 2025. The company recorded a six-month net loss of $143.2 million and a three-month loss of $93.8 million, driven in part by a $44.6 million non-cash impairment of long-lived assets related to its Bothell and Seattle facilities. Total assets fell to $361.6 million from $501.0 million at year-end, and cash and cash equivalents declined to $71.3 million on the balance sheet. Long-term liabilities include $117.1 million of contingent consideration and $8.6 million of success payment liabilities tied to prior acquisitions and license agreements. Management completed an ATM facility and, subsequently, an underwritten offering that together provided additional net proceeds (including $70.0 million from the August offering and $28.6 million raised under the ATM after June 30), and believes available liquidity plus those proceeds will fund planned operations for at least one year. The company reported positive clinical signals for an investigator-sponsored islet transplant (UP421), including C-peptide production and PET-MRI evidence of engraftment, and announced portfolio prioritization toward T1D, B-cell autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.
Sana Biotechnology announced it has issued a press release reporting its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The company states the press release is being furnished and not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The 8-K lists Exhibit 99.1 and an Inline XBRL cover page, identifies the registrant as an emerging growth company, and is signed by Acting Chief Financial Officer Susan Wyrick. The company trades on Nasdaq under the ticker SANA.
On 6-Aug-2025 Sana Biotechnology, Inc. (SANA) executed an Underwriting Agreement with Morgan Stanley, Goldman Sachs and BofA to raise capital through a public offering.
- Securities: 20,895,522 common shares at $3.35 and 1,492,537 pre-funded warrants at $3.3499 per underlying share.
- Underwriter purchase price: $3.149 per share and $3.1489 per warrant.
- Greenshoe: 30-day option for up to 3,358,208 additional shares.
- Net proceeds: ≈$70 million to SANA, assuming no option exercise and after fees.
- Closing: expected 8-Aug-2025, subject to customary conditions.
- Warrant terms: $0.0001 exercise price, no expiration, 4.99 % ownership cap (adjustable to ≤19.99 %), cash or cashless exercise, standard anti-dilution and Fundamental Transaction protections.
The raise is being made from shelf registration statement No. 333-277584. All securities are issued by the company, providing immediate liquidity while increasing the share count and potential future dilution.
Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.
Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing β-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.
Sana Biotechnology (NASDAQ: SANA) filed an 8-K disclosing key Q2-Q3 developments. The company estimates it held $90.1 million in cash, cash equivalents and marketable securities on 31 Jul 2025. Between 1 Apr and 6 Aug 2025 it raised $29.1 million of net proceeds through the sale of 7,441,376 common shares under its at-the-market program.
Sana will record a $40-45 million non-cash impairment in May 2025 linked to suspended build-out and planned subleases of its Bothell and Seattle facilities. Operationally, June 2025 six-month data from the investigator-sponsored UP421 trial met all primary and secondary endpoints, demonstrating insulin-producing β-cell function without immunosuppression; results were later published in NEJM. Pre-clinical candidate SC451 advanced following a favorable FDA INTERACT meeting. Conversely, Senior VP & Head of the Hypoimmune Platform Dr. Sonja Schrepfer resigned. All financial figures are unaudited and subject to change.
Sana Biotechnology, Inc. (NASDAQ: SANA) filed a Form 8-K to disclose a material scientific milestone. On June 23 2025, the company announced positive six-month results from an investigator-sponsored, first-in-human study evaluating UP421—an allogeneic primary islet cell therapy engineered with Sana’s proprietary hypoimmune technology—in a patient with type 1 diabetes. Notably, the transplant was performed without any immunosuppression, underscoring a key differentiator of the platform. The announcement was furnished as Exhibit 99.1 to the report and no other financial metrics, earnings data or transactions were included.
The filing is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits). It confirms that the press release dated June 23 2025 is now part of the public record. No changes to guidance, capitalization or management were reported. The disclosure highlights continued progress of Sana’s cell-engineering pipeline and potentially de-risks the hypoimmune approach, but investors must await fuller clinical datasets before drawing definitive efficacy or commercial conclusions.